Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy.
OBJECTIVE
To determine whether there is an association between complement factor H (CFH) or LOC387715 genotypes and response to treatment with photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD).


METHODS
Sixty-nine patients being treated for neovascular AMD with PDT were genotyped for the CFH Y402H and LOC387715 A69S polymorphisms by allele-specific digestion of PCR products. AMD phenotypes were characterized by clinical examination, fundus photography, and fluorescein angiography.


RESULTS
Adjusting for age, pre-PDT visual acuity (VA), and lesion type, mean VA after PDT was significantly worse for the CFH TT genotype than for the TC or CC genotypes (P=0.05). Post-PDT VA was significantly worse for the CFH TT genotype in the subgroup of patients with predominantly classic choroidal neovascular lesions (P=0.04), but not for the patients with occult lesions (P=0.22). For the LOC387715 A69S variant, there was no significant difference among the genotypes in response to PDT therapy.


CONCLUSIONS
The CFH Y402H variant was associated with a response to PDT treatment in this study. Patients with the CFH TT genotype fared significantly worse with PDT than did those with the CFH TC and CC genotypes, suggesting a potential relationship between CFH genotype and response to PDT.
Brantley
M A
MA
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA. brantley@vision.wustl.edu
Edelstein
S L
SL
King
J M
JM
Plotzke
M R
MR
Apte
R S
RS
Kymes
S M
SM
Shiels
A
A
D000368:Aged; D000369:Aged, 80 and over; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D017242:Complement Factor H / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D010778:Photochemotherapy; D011379:Prognosis; D011506:Proteins / Q000235:genetics*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000235:genetics / Q000502:physiology
C514392:ARMS2 protein, human; C493495:CFH protein, human; D011506:Proteins; D017242:Complement Factor H